Drug Search Results
More Filters [+]

Zetomipzomib

Alternative Names: Zetomipzomib, kzr-616, kzr 616, kzr616
Latest Update: 2024-10-10
Latest Update Note: Clinical Trial Update

Product Description

Zetomipzomib (KZR-616) is a first-in-class, selective immunoproteasome inhibitor for a range of autoimmune diseases. Immunoproteasomes play an important role in regulating the normal function of the immune system and when inhibited, multiple pathways involved in inflammatory cytokine production and immune effector cell activity – including macrophages, B cells and T cells – are also inhibited. Since the pathways regulated by immunoproteasomes are involved in the pathogenesis of many autoimmune diseases, zetomipzomib offers a “pipeline in a drug” approach, with the potential to be a treatment option for a broad range of autoimmune conditions. (Sourced from: https://www.kezarlifesciences.com/pipeline/zetomipzomib)

Mechanisms of Action: Proteasome Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Subcutaneous,Intravenous

FDA Designation: Orphan Drug - Dermatomyositis|Myositis|Polymyositis *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Kezar Life Sciences
Company Location: SOUTH SAN FRANCISCO CA 94080
Company CEO: John Fowler
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Zetomipzomib

Countries in Clinic: Argentina, Australia, Brazil, China, Colombia, Croatia, Czech Republic, France, Germany, Greece, Guatemala, India, Italy, Korea, Malaysia, Mexico, Peru, Philippines, Poland, Portugal, Puerto Rico, Russia, Serbia, South Africa, Spain, Taiwan, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 9

Highest Development Phases

Phase 2: Dermatomyositis|Hepatitis A|Hepatitis, Autoimmune|Lupus Erythematosus, Systemic|Lupus Nephritis|Polymyositis

Phase 1: Arthritis, Rheumatoid

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PALIZADE

P2

Suspended

Lupus Nephritis

2026-05-01

KZR-616-202

P2

Unknown Status

Lupus Nephritis

2026-04-30

PORTOLA

P2

Active, not recruiting

Hepatitis A|Hepatitis, Autoimmune

2025-02-01

2020-004382-39

P2

Active, not recruiting

Polymyositis|Dermatomyositis

2023-04-02

Recent News Events